Roche dismisses Novo Nordisk as potential threat on lucrative hemophilia market
Novo Nordisk's future hemophilia drugs face a difficult challenge in reconquering the profitable hemophilia drug market, says CEO at Roche, which is currently shepherding a big part of the loyal hemophiliac flock.
BY Leonora beck, TRANSLATED BY DANIEL PEDERSEN
The pharmaceutical giant Roche has in a short time seized large portions of the world's hemophiliac market, a lead that the Swiss company and competitor of Novo Nordisk expects to maintain.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
